Drug discovery reinvented.

P42med is an innovative early-stage biotechnology startup focused on developing cutting-edge in silico drug design solutions to address the challenges of GPCR modulation.

Leveraging the power of computational approaches, we aim to design allosteric transmembrane modulators.

Allosteric transmembrane modulatorswhich hold the potential to fine-tune receptor activity, increasing specificity and signaling bias.   Our vision is to transform the drug discovery process through computational techniques, ultimately leading to the development of novel therapies that improve and extend people's lives.  

Our innovation is a novel drug candidate that utilizes the mechanism of transmembrane allosteric modulation of mu opioid receptors.

This approach offers several advantages including lower risks of overdose and addiction, lower side effects, and the potential for safer chronic use. Our drug has the potential to be used as a companion drug to enhance existing therapies or reduce the dosage of other opioids in combined therapies, and could expand the customer base for opioid-based treatments. This novel approach to drug design provides a unique solution to the challenges posed by traditional opioid treatments.


We are driven by a science-led approach to in silico drug design that pushes the boundaries of what is possible.

Our focus on peptide flexibility and configurational entropy has allowed us to achieve optimal drug designs that target hard-to-reach, membrane-buried regions of receptors.   By fine-tuning the configurational entropy of the system, we are able to achieve optimal binding affinities for our drug candidates, resulting in more specific and effective drug candidates.   Our constantly evolving proprietary software, utilizes recurrent networks and transformers for analyzing sequence data and convolutional models for structural inputs. We are always exploring new architectures and approaches to improve our performance and accuracy.  

Key areas of interest 

Peptides are an exciting class of drug candidates that offer a unique
combination of benefits from both small molecule

Orthosteric interactions

Our team has successfully developed a dual peptidic agonist with our in silico drug design methods. This project involved the identification of optimal orthosteric interactions to achieve high binding affinity and selectivity for the targets. Our platform enabled us to rapidly iterate through many potential compounds and optimize them for efficacy and safety. 


Currently we focus on the design of allosteric modulators. Our methods have been used to design positive modulators for GPCR targets that have shown promising early-stage in vitro results. By targeting allosteric sites, we can develop drugs with greater selectivity and fewer side effects than traditional drugs. 

Non-GPCR applications

Our platform is not limited to GPCR targets. For example, designed MHC–II binding peptides in epitope identification project. This  required the use of machine learning algorithms to predict binding affinity to MHC–II targets. The resulting peptides showed high binding affinity and were useful in identifying novel epitopes for vaccine design. 


We believe that by partnering with like-minded teams, we can accelerate the translation of groundbreaking research into life-changing medicines. We are open to partnering with startups, scientific teams, and pharmaceutical companies to accelerate the translation of groundbreaking research into life-changing medicines. Our expertise in in silico drug design can be applied to drug candidates aligned with the company’s pipeline, bringing novel therapies to market faster. We are willing to explore small-scale pilot projects to showcase the value of our methods and establish long-term partnerships to deliver innovative solutions to patients.